ABT FY 2019 Earnings Report — Abbott Laboratories Revenue & Financial Results | Market Cap Arena

Abbott LaboratoriesABT

FY 2019 Earnings

Reported February 21, 2020

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2019	Prior Q	FY 2018	QoQ Change	YoY Change
Revenue	$31.9B	—	$30.6B	—	4.3%
Op. Income	$4.6B	—	$3.8B	—	19.4%
Gross Margin	52.3%	—	51.7%	—	0.6pp
Net Margin	11.6%	—	7.7%	—	3.8pp
EPS (Diluted)	$2.06	—	$1.34	—	53.7%
Free Cash Flow	$4.5B	—	$4.9B	—	-8.3%

Revenue Flow

Item	Amount
REVENUE	$31.9B
Cost of Revenue	$15.2B
GROSS PROFIT	$16.7B
R&D Expenses	$2.4B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$9.7B
Other Expenses	$0
Operating Expenses	$12.1B
Cost & Expenses	$27.3B
OPERATING INCOME	$4.6B
Interest Income	$94M
Interest Expense	$818M
Other Income/Expenses	-$514M
INCOME BEFORE TAX	$4.1B
Income Tax Expense	$390M
Net Income from Continuing Ops	$3.7B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$3.7B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$3.7B
D&A	$3.0B
EBIT	$4.9B
EBITDA	$7.9B
EPS	$2
EPS Diluted	$2

Income Statement

Item	Amount
REVENUE	$31.9B
Cost of Revenue	$15.2B
GROSS PROFIT	$16.7B
R&D Expenses	$2.4B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$9.7B
Other Expenses	$0
Operating Expenses	$12.1B
Cost & Expenses	$27.3B
OPERATING INCOME	$4.6B
Interest Income	$94M
Interest Expense	$818M
Other Income/Expenses	-$514M
INCOME BEFORE TAX	$4.1B
Income Tax Expense	$390M
Net Income from Continuing Ops	$3.7B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$3.7B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$3.7B
D&A	$3.0B
EBIT	$4.9B
EBITDA	$7.9B
EPS	$2
EPS Diluted	$2

Cash Flow Statement

Item	Amount
Net Income	$3.7B
Depreciation & Amortization	$3.0B
Stock-Based Compensation	$519M
Deferred Income Tax	$0
Other Non-Cash Items	$247M
Change in Working Capital	-$1.3B
OPERATING CASH FLOW	$6.1B
Capital Expenditure	-$1.6B
Acquisitions (Net)	-$122M
Purchases of Investments	-$103M
Sales/Maturities of Investments	$21M
Other Investing Activities	$27M
NET CASH FROM INVESTING	-$1.8B
Net Debt Issuance	-$1.6B
Common Stock Repurchased	-$718M
Common Dividends Paid	-$2.3B
Other Financing Activities	$298M
NET CASH FROM FINANCING	-$4.3B
FREE CASH FLOW	$4.5B
Net Change in Cash	$16M

Balance Sheet

Item	Amount
Cash & Equivalents	$3.9B
Short-Term Investments	$280M
Net Receivables	$5.4B
Inventory	$4.3B
Other Current Assets	$1.8B
TOTAL CURRENT ASSETS	$15.7B
PP&E (Net)	$9.0B
Goodwill	$23.2B
Intangible Assets	$17.0B
Long-Term Investments	$931M
Tax Assets	$0
Other Non-Current Assets	$2.1B
TOTAL NON-CURRENT ASSETS	$52.2B
TOTAL ASSETS	$67.9B
Account Payables	$3.3B
Short-Term Debt	$1.7B
Deferred Revenue	$0
Other Current Liabilities	$4.5B
TOTAL CURRENT LIABILITIES	$10.9B
Long-Term Debt	$16.7B
Deferred Revenue NC	$0
Deferred Tax Liabilities	$2.1B
Other Non-Current Liabilities	$6.2B
TOTAL NON-CURRENT LIABILITIES	$25.7B
TOTAL LIABILITIES	$36.6B
Common Stock	$23.9B
Additional Paid-In Capital	$0
Retained Earnings	$25.8B
Treasury Stock	-$10.1B
Accum. Other Comp. Income	-$8.5B
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$31.1B
Minority Interest	$213M
TOTAL EQUITY	$31.3B
TOTAL LIABILITIES & EQUITY	$67.9B
Total Debt	$19.1B
Net Debt	$15.2B